Ankylosingselected
selected 时间:2021-05-21 阅读:()
Item4.
InformationontheCompany1SelecteddevelopmentprojectsYearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseABL001asciminibBCRABLinhibitorChronicmyeloidleukemia,3rdlineOncologyOral20162021/IIIACZ885canakinumabAntiinterleukin1beta2ndlinenonsmallcelllungcancerOncologySubcutaneousinjection20172021/IIImonoclonalantibody1stlinenonsmallcelllungcancerOncologySubcutaneousinjection20172021/IIIAdjuvantnonsmallcelllungcancerOncologySubcutaneousinjection20172022/IIIAVXS1011onasemno-SurvivalmotorneuronSpinalmuscularatrophyNeuroscienceIntravenousinfusion2018USapprovedgeneabepar-(SMN)gene(IVformulation)EUregistrationvovecreplacementtherapySpinalmuscularatrophyNeuroscienceIntrathecalinjection20182020/I(ITformulation)2AVXS201TBDMethylCpGbindingRettsyndromeNeuroscienceIntrathecalinjection20182023/Iprotein2(MECP2)genereplacementtherapyBYL7193alpelisibPI3KalphainhibitorPIK3CAmutanthormonereceptorpositiveOncologyOral2018USapproved(HR+)/humanepidermalgrowthfactorEUregistrationreceptor2negative(HER2)postmenopausaladvancedbreastcancer,2ndline(+fulvestrant)PIK3CA-relatedovergrowthspectrumOncologyOral20192020/IIITriplenegativebreastcancerOncologyOral20192023/IIIHormonereceptor-negative(HR-)/humanOncologyOral20192023/IIIepidermalgrowthfactorreceptor2-positive(HER2+)advancedbreastcancerOvariancancerOncologyOral20192023/IIIHeadandnecksquamouscellcarcinomaOncologyOral2019≥2024/IIICEE321TBDPan-JAKinhibitorAtopicdermatitisImmunology,Topical2019≥2024/IIHepatologyandDermatologyCFZ533iscalimabBlocking,nondepleting,SolidorgantransplantationImmunology,Intravenousinfusion20172023/IIantiCD40monoclonalHepatologyandantibodyDermatologySjgren'ssyndromeImmunology,Intravenousinfusion2018≥2024/IIHepatologyandDermatologyCosentyxsecukinumabAntiinterleukin17NonradiographicaxialspondyloarthritisImmunology,Subcutaneousinjection2015US/EUmonoclonalantibodyHepatologyandregistrationDermatologyPsoriaticarthritisheadtoheadstudyImmunology,Subcutaneousinjection20152020/IIIversusHumira(adalimumab)HepatologyandDermatologyAnkylosingspondylitisheadtoheadstudyImmunology,Subcutaneousinjection20152022/IIIversusSandozbiosimilarHyrimozHepatologyand(adalimumab)DermatologyHidradenitissuppurativaImmunology,Intravenousinfusion20172022/IIIHepatologyandDermatologyGiantcellarteritisImmunology,Intravenousinfusion2018≥2024/IIHepatologyandDermatologyLichenplanusImmunology,Intravenousinfusion2019≥2024/IIHepatologyandDermatologyCSJ117TBDAntithymicstromalSevereasthmaRespiratoryInhalation20182023/IIlymphopoietinmonoclonalantibodyfragmentECF843TBDBoundarylubricantDryeyeOphthalmologyEyedrops20172022/IIEntrestovalsartanandAngiotensinreceptor/ChronicheartfailurewithpreservedCardiovascular,Oral20122020/IIIsacubitrilneprilysininhibitorejectionfractionRenal(assodiumandMetabolismsaltcomplex)PostacutemyocardialinfarctionCardiovascular,Oral20152021/IIIRenalandMetabolism1ApprovedintheUSasZolgensmaforspinalmuscularatrophy(IVformulation)2TheFDAhasplacedapartialclinicalholdonAVXS-101intrathecaltrialsforspinalmuscularatrophypatientsbasedonfindingsinasmallpreclinicalanimalstudy.
3ApprovedintheUSasPiqrayforPIK3CAmutantHR+/HER2-postmenopausaladvancedbreastcancer,2ndline(+fulvestrant)Item4.
InformationontheCompany2YearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseINC280capmatinibc-METinhibitorNonsmallcelllungcancerOncologyOral2014USregistrationSolidtumorsOncologyOral2019≥2024/IIJakaviruxolitinibJAK1/2inhibitorAcutegraftversushostdiseaseOncologyOral20162021/IIIChronicgraftversushostdiseaseOncologyOral20162021/IIIKAE609cipargaminPfATP4inhibitorMalariaEstablishedOral2012≥2024/IIMedicinesSeveremalariaEstablishedOral2019≥2024/IIMedicinesKAF156ganaplacideImidazolopiperazinesMalariaEstablishedOral2014≥2024/IIderivativeMedicinesKisqaliribociclibCDK4/6inhibitorHR+/HER2breastcancer(adjuvant)OncologyOral20182022/IIIKJX839inclisiranSmall-interferingRNAHyperlipidemiaCardiovascular,Subcutaneousinjection2019US/EU(PCSK9)RenalregistrationandMetabolismSecondarypreventionofcardiovascularCardiovascular,Subcutaneousinjection2019≥2024/IIIeventsinpatientswithelevatedlevelsRenalofLDL-CandMetabolismKymriahtisagen-CD19targetedchimericRelapsed/refractoryfollicularlymphomaOncologyIntravenousinfusion20172021/IIlecleucelantigenreceptorTcellimmunotherapyRelapsed/refractorydiffuselargeBcellOncologyIntravenousinfusion20182021/IIIlymphomain1strelapseRelapsed/refractorydiffuselargeBcellOncologyIntravenousinfusion2017≥2024/IIlymphoma(+pembrolizumab)LAM320clofazimineMycobacterialMultidrugresistanttuberculosisEstablishedOral20162021/IIIDNAbindingMedicinesLJC242tropifexor,FXRagonistandNonalcoholicsteatohepatitisImmunology,Oral2017≥2024/IIcenicrivirocCCR2/5inhibitorHepatologyand(infixed-doseDermatologycombination)LJN452tropifexorFXRagonistNonalcoholicsteatohepatitisImmunology,Oral2015≥2024/IIHepatologyandDermatologyLMI070branaplamSMN2RNAsplicingSpinalmuscularatrophyNeuroscienceOral2017≥2024/IImodulatorLNP023TBDFactorBinhibitorIgAnephropathyCardiovascular,Oral20182023/IIRenalandMetabolismC3glomerulopathyCardiovascular,Oral20182023/IIRenalandMetabolismParoxysmalnocturnalhemoglobinuriaCardiovascular,Oral20192023/IIRenalandMetabolismMembranousnephropathyCardiovascular,Oral2018≥2024/IIRenalandMetabolismLOU064TBDBTKinhibitorChronicspontaneousurticariaImmunology,Oral20172023/IIHepatologyandDermatology177Lu-TBDTargetedDNAMetastaticcastration-resistantOncologyIntravenousinfusion20182020/IIIPSMA-617destructionviaprostatecancerbeta-particleradiationLXE408TBDKinetoplastidVisceralleishmaniasisEstablishedOral2019≥2024/IIproteasomeinhibitorMedicinesMBG453TBDTIM-3antagonistMyelodysplasticsyndromeOncologyIntravenousinfusion20182021/IIAcutemyeloidleukemiaOncologyIntravenousinfusion2019≥2024/IIOMB157ofatumumabAntiCD20monoclonalRelapsingmultiplesclerosisNeuroscienceSubcutaneousinjection2015US/EUantibodyregistrationPDR001spartalizumabAntiPD1monoclonalMetastaticBRAFV600+OncologyIntravenousinfusion20172020/IIIantibodymelanoma(w/Tafinlar+Mekinist)Metastaticmelanoma(combo)OncologyIntravenousinfusion20172023/IIQBW251TBDCFTRpotentiatorChronicobstructivepulmonarydiseaseRespiratoryOral2017≥2024/IIQGE031ligelizumabHighaffinityantiIgEChronicspontaneousurticaria/Immunology,Subcutaneousinjection20172021/IIImonoclonalantibodychronicidiopathicurticariaHepatologyandDermatologyQMF149indacaterol,Longactingbeta2AsthmaRespiratoryInhalation2019EUregistrationmometasoneadrenergicagonistandfuroateinhaledcorticosteroid(infixeddosecombination)Item4.
InformationontheCompany3YearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseQVM149indacaterol,Longactingbeta2AsthmaRespiratoryInhalation2019EUregistrationmometasoneadrenergicagonist,furoate,longactingmuscarinicglyco-antagonistandinhaledpyrroniumcorticosteroidbromide(infixeddosecombination)RTH2584brolucizumabAntiVEGFsinglechainNeovascular(wet)agerelatedmacularOphthalmologyIntravitrealinjection2019USapprovedantibodyfragmentdegenerationEUregistrationDiabeticmacularedemaOphthalmologyIntravitrealinjection20172021/IIIRetinalveinocclusionOphthalmologyIntravitrealinjection20182023/IIIProliferativediabeticretinopathyOphthalmologyIntravitrealinjection20192023/IIISAF312TBDTRPV1antagonistChronicocularsurfacepainOphthalmologyTopical2019≥2024/IISEG1015crizanlizumabPselectininhibitorSicklecelldiseaseOncologyIntravenousinfusion2019USapprovedEUregistrationTQJ230TBDAnti-apo(a)antisenseSecondarypreventionofcardiovascularCardiovascular,Subcutaneousinjection2018≥2024/IIIoligonucleotideeventsinpatientswithelevatedlevelsRenalandoflipoprotein(a)MetabolismUNR844TBDReductionofPresbyopiaCardiovascular,Eyedrops2017≥2024/IIdisulfidebondsRenalandMetabolismVAY736ianalumabAntiBAFF(BcellAutoimmunehepatitisImmunology,Subcutaneousinjection2016≥2024/IIactivatingfactor)HepatologyandmonoclonalantibodyDermatologyPrimarySjgren'ssyndromeImmunology,Subcutaneousinjection2015≥2024/IIHepatologyandDermatologyVPM087TBDInterleukin-1betaColorectalcancer,1stline;OncologyIntravenousinfusion2018≥2024/Ineutralizationrenalcellcarcinoma,1stlinemonoclonalantibodyXolairomalizumabAntiIgEmonoclonalNasalpolypsRespiratorySubcutaneousinjection2017US/EUantibodyregistrationFoodallergyRespiratorySubcutaneousinjection20192021/IIIZPL389adriforantHistamineH4receptorAtopicdermatitisImmunology,Oral2017≥2024/IIantagonistHepatologyandDermatology4ApprovedintheUSasBeovuforneovascular(wet)agerelatedmaculardegeneration5ApprovedintheUSasAdakveoforsicklecelldisease
InformationontheCompany1SelecteddevelopmentprojectsYearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseABL001asciminibBCRABLinhibitorChronicmyeloidleukemia,3rdlineOncologyOral20162021/IIIACZ885canakinumabAntiinterleukin1beta2ndlinenonsmallcelllungcancerOncologySubcutaneousinjection20172021/IIImonoclonalantibody1stlinenonsmallcelllungcancerOncologySubcutaneousinjection20172021/IIIAdjuvantnonsmallcelllungcancerOncologySubcutaneousinjection20172022/IIIAVXS1011onasemno-SurvivalmotorneuronSpinalmuscularatrophyNeuroscienceIntravenousinfusion2018USapprovedgeneabepar-(SMN)gene(IVformulation)EUregistrationvovecreplacementtherapySpinalmuscularatrophyNeuroscienceIntrathecalinjection20182020/I(ITformulation)2AVXS201TBDMethylCpGbindingRettsyndromeNeuroscienceIntrathecalinjection20182023/Iprotein2(MECP2)genereplacementtherapyBYL7193alpelisibPI3KalphainhibitorPIK3CAmutanthormonereceptorpositiveOncologyOral2018USapproved(HR+)/humanepidermalgrowthfactorEUregistrationreceptor2negative(HER2)postmenopausaladvancedbreastcancer,2ndline(+fulvestrant)PIK3CA-relatedovergrowthspectrumOncologyOral20192020/IIITriplenegativebreastcancerOncologyOral20192023/IIIHormonereceptor-negative(HR-)/humanOncologyOral20192023/IIIepidermalgrowthfactorreceptor2-positive(HER2+)advancedbreastcancerOvariancancerOncologyOral20192023/IIIHeadandnecksquamouscellcarcinomaOncologyOral2019≥2024/IIICEE321TBDPan-JAKinhibitorAtopicdermatitisImmunology,Topical2019≥2024/IIHepatologyandDermatologyCFZ533iscalimabBlocking,nondepleting,SolidorgantransplantationImmunology,Intravenousinfusion20172023/IIantiCD40monoclonalHepatologyandantibodyDermatologySjgren'ssyndromeImmunology,Intravenousinfusion2018≥2024/IIHepatologyandDermatologyCosentyxsecukinumabAntiinterleukin17NonradiographicaxialspondyloarthritisImmunology,Subcutaneousinjection2015US/EUmonoclonalantibodyHepatologyandregistrationDermatologyPsoriaticarthritisheadtoheadstudyImmunology,Subcutaneousinjection20152020/IIIversusHumira(adalimumab)HepatologyandDermatologyAnkylosingspondylitisheadtoheadstudyImmunology,Subcutaneousinjection20152022/IIIversusSandozbiosimilarHyrimozHepatologyand(adalimumab)DermatologyHidradenitissuppurativaImmunology,Intravenousinfusion20172022/IIIHepatologyandDermatologyGiantcellarteritisImmunology,Intravenousinfusion2018≥2024/IIHepatologyandDermatologyLichenplanusImmunology,Intravenousinfusion2019≥2024/IIHepatologyandDermatologyCSJ117TBDAntithymicstromalSevereasthmaRespiratoryInhalation20182023/IIlymphopoietinmonoclonalantibodyfragmentECF843TBDBoundarylubricantDryeyeOphthalmologyEyedrops20172022/IIEntrestovalsartanandAngiotensinreceptor/ChronicheartfailurewithpreservedCardiovascular,Oral20122020/IIIsacubitrilneprilysininhibitorejectionfractionRenal(assodiumandMetabolismsaltcomplex)PostacutemyocardialinfarctionCardiovascular,Oral20152021/IIIRenalandMetabolism1ApprovedintheUSasZolgensmaforspinalmuscularatrophy(IVformulation)2TheFDAhasplacedapartialclinicalholdonAVXS-101intrathecaltrialsforspinalmuscularatrophypatientsbasedonfindingsinasmallpreclinicalanimalstudy.
3ApprovedintheUSasPiqrayforPIK3CAmutantHR+/HER2-postmenopausaladvancedbreastcancer,2ndline(+fulvestrant)Item4.
InformationontheCompany2YearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseINC280capmatinibc-METinhibitorNonsmallcelllungcancerOncologyOral2014USregistrationSolidtumorsOncologyOral2019≥2024/IIJakaviruxolitinibJAK1/2inhibitorAcutegraftversushostdiseaseOncologyOral20162021/IIIChronicgraftversushostdiseaseOncologyOral20162021/IIIKAE609cipargaminPfATP4inhibitorMalariaEstablishedOral2012≥2024/IIMedicinesSeveremalariaEstablishedOral2019≥2024/IIMedicinesKAF156ganaplacideImidazolopiperazinesMalariaEstablishedOral2014≥2024/IIderivativeMedicinesKisqaliribociclibCDK4/6inhibitorHR+/HER2breastcancer(adjuvant)OncologyOral20182022/IIIKJX839inclisiranSmall-interferingRNAHyperlipidemiaCardiovascular,Subcutaneousinjection2019US/EU(PCSK9)RenalregistrationandMetabolismSecondarypreventionofcardiovascularCardiovascular,Subcutaneousinjection2019≥2024/IIIeventsinpatientswithelevatedlevelsRenalofLDL-CandMetabolismKymriahtisagen-CD19targetedchimericRelapsed/refractoryfollicularlymphomaOncologyIntravenousinfusion20172021/IIlecleucelantigenreceptorTcellimmunotherapyRelapsed/refractorydiffuselargeBcellOncologyIntravenousinfusion20182021/IIIlymphomain1strelapseRelapsed/refractorydiffuselargeBcellOncologyIntravenousinfusion2017≥2024/IIlymphoma(+pembrolizumab)LAM320clofazimineMycobacterialMultidrugresistanttuberculosisEstablishedOral20162021/IIIDNAbindingMedicinesLJC242tropifexor,FXRagonistandNonalcoholicsteatohepatitisImmunology,Oral2017≥2024/IIcenicrivirocCCR2/5inhibitorHepatologyand(infixed-doseDermatologycombination)LJN452tropifexorFXRagonistNonalcoholicsteatohepatitisImmunology,Oral2015≥2024/IIHepatologyandDermatologyLMI070branaplamSMN2RNAsplicingSpinalmuscularatrophyNeuroscienceOral2017≥2024/IImodulatorLNP023TBDFactorBinhibitorIgAnephropathyCardiovascular,Oral20182023/IIRenalandMetabolismC3glomerulopathyCardiovascular,Oral20182023/IIRenalandMetabolismParoxysmalnocturnalhemoglobinuriaCardiovascular,Oral20192023/IIRenalandMetabolismMembranousnephropathyCardiovascular,Oral2018≥2024/IIRenalandMetabolismLOU064TBDBTKinhibitorChronicspontaneousurticariaImmunology,Oral20172023/IIHepatologyandDermatology177Lu-TBDTargetedDNAMetastaticcastration-resistantOncologyIntravenousinfusion20182020/IIIPSMA-617destructionviaprostatecancerbeta-particleradiationLXE408TBDKinetoplastidVisceralleishmaniasisEstablishedOral2019≥2024/IIproteasomeinhibitorMedicinesMBG453TBDTIM-3antagonistMyelodysplasticsyndromeOncologyIntravenousinfusion20182021/IIAcutemyeloidleukemiaOncologyIntravenousinfusion2019≥2024/IIOMB157ofatumumabAntiCD20monoclonalRelapsingmultiplesclerosisNeuroscienceSubcutaneousinjection2015US/EUantibodyregistrationPDR001spartalizumabAntiPD1monoclonalMetastaticBRAFV600+OncologyIntravenousinfusion20172020/IIIantibodymelanoma(w/Tafinlar+Mekinist)Metastaticmelanoma(combo)OncologyIntravenousinfusion20172023/IIQBW251TBDCFTRpotentiatorChronicobstructivepulmonarydiseaseRespiratoryOral2017≥2024/IIQGE031ligelizumabHighaffinityantiIgEChronicspontaneousurticaria/Immunology,Subcutaneousinjection20172021/IIImonoclonalantibodychronicidiopathicurticariaHepatologyandDermatologyQMF149indacaterol,Longactingbeta2AsthmaRespiratoryInhalation2019EUregistrationmometasoneadrenergicagonistandfuroateinhaledcorticosteroid(infixeddosecombination)Item4.
InformationontheCompany3YearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseQVM149indacaterol,Longactingbeta2AsthmaRespiratoryInhalation2019EUregistrationmometasoneadrenergicagonist,furoate,longactingmuscarinicglyco-antagonistandinhaledpyrroniumcorticosteroidbromide(infixeddosecombination)RTH2584brolucizumabAntiVEGFsinglechainNeovascular(wet)agerelatedmacularOphthalmologyIntravitrealinjection2019USapprovedantibodyfragmentdegenerationEUregistrationDiabeticmacularedemaOphthalmologyIntravitrealinjection20172021/IIIRetinalveinocclusionOphthalmologyIntravitrealinjection20182023/IIIProliferativediabeticretinopathyOphthalmologyIntravitrealinjection20192023/IIISAF312TBDTRPV1antagonistChronicocularsurfacepainOphthalmologyTopical2019≥2024/IISEG1015crizanlizumabPselectininhibitorSicklecelldiseaseOncologyIntravenousinfusion2019USapprovedEUregistrationTQJ230TBDAnti-apo(a)antisenseSecondarypreventionofcardiovascularCardiovascular,Subcutaneousinjection2018≥2024/IIIoligonucleotideeventsinpatientswithelevatedlevelsRenalandoflipoprotein(a)MetabolismUNR844TBDReductionofPresbyopiaCardiovascular,Eyedrops2017≥2024/IIdisulfidebondsRenalandMetabolismVAY736ianalumabAntiBAFF(BcellAutoimmunehepatitisImmunology,Subcutaneousinjection2016≥2024/IIactivatingfactor)HepatologyandmonoclonalantibodyDermatologyPrimarySjgren'ssyndromeImmunology,Subcutaneousinjection2015≥2024/IIHepatologyandDermatologyVPM087TBDInterleukin-1betaColorectalcancer,1stline;OncologyIntravenousinfusion2018≥2024/Ineutralizationrenalcellcarcinoma,1stlinemonoclonalantibodyXolairomalizumabAntiIgEmonoclonalNasalpolypsRespiratorySubcutaneousinjection2017US/EUantibodyregistrationFoodallergyRespiratorySubcutaneousinjection20192021/IIIZPL389adriforantHistamineH4receptorAtopicdermatitisImmunology,Oral2017≥2024/IIantagonistHepatologyandDermatology4ApprovedintheUSasBeovuforneovascular(wet)agerelatedmaculardegeneration5ApprovedintheUSasAdakveoforsicklecelldisease
- Ankylosingselected相关文档
- frequencyselected
- mesonselected
- lowestselected
- approachselected
- schemesselected
- detailedselected
RAKsmart新年钜惠：E3服务器秒杀$30/月起,新上韩国服务器,香港/日本/美国站群服务器,VPS月付$1.99起,GPU服务器,高防服务器_vps香港
RAKsmart发布了新年钜惠活动，即日起到2月28日，商家每天推出限量服务器秒杀，美国服务器每月30美元起，新上了韩国服务器、GPU服务器、香港/日本/美国常规+站群服务器、1-10Gbps不限流量大带宽服务器等大量库存；VPS主机全场提供7折优惠码，同时针对部分特惠套餐无码直购每月仅1.99美元，支持使用PayPal或者支付宝等方式付款，有中英文网页及客服支持。爆款秒杀10台/天可选精品网/大...
百驰云（19/月），高性能服务器，香港三网CN2 2核2G 10M 国内、香港、美国、日本、VPS、物理机、站群全站7.5折，无理由退换，IP免费换！
百驰云成立于2017年，是一家新国人IDC商家，且正规持证IDC/ISP/CDN，商家主要提供数据中心基础服务、互联网业务解决方案，及专属服务器租用、云服务器、云虚拟主机、专属服务器托管、带宽租用等产品和服务。百驰云提供源自大陆、香港、韩国和美国等地骨干级机房优质资源，包括BGP国际多线网络，CN2点对点直连带宽以及国际顶尖品牌硬件。专注为个人开发者用户,中小型,大型企业用户提供一站式核心网络云端...
[黑五]ProfitServer新加坡/德国/荷兰/西班牙VPS五折,不限流量KVM月付2.88美元起
ProfitServer已开启了黑色星期五的促销活动，一直到本月底，商家新加坡、荷兰、德国和西班牙机房VPS直接5折，无码直购最低每月2.88美元起，不限制流量，提供IPv4+IPv6。这是一家始于2003年的俄罗斯主机商，提供虚拟主机、VPS、独立服务器、SSL证书、域名等产品，可选数据中心包括俄罗斯、法国、荷兰、美国、新加坡、拉脱维亚、捷克、保加利亚等多个国家和地区。我们随便以一个数据中心为例...
selected为你推荐
-
Javamedia支持ipadipadwifiIPAD连上了WIFI，但是无法上网，急！！win10关闭445端口如何进入注册表修改关闭445端口css下拉菜单如何使用HTML和CSS制作下拉菜单ms17-010win10华为 slatl10是什么型号联通版iphone4s苹果4s是联通版，或移动版，或全网通如何知道？谷歌sb为什么搜索SB第一个是google？迅雷快鸟迅雷快鸟这种强盗软件不违规吗？csshack什么是Css Hack？ie6，7，8的hack分别是什么